Q1 Earnings Forecast for STOK Issued By HC Wainwright

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Research analysts at HC Wainwright issued their Q1 2025 EPS estimates for shares of Stoke Therapeutics in a research report issued on Wednesday, March 19th. HC Wainwright analyst A. Fein expects that the company will earn ($0.53) per share for the quarter. HC Wainwright has a “Buy” rating and a $47.00 price objective on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ Q2 2025 earnings at ($0.54) EPS.

STOK has been the topic of several other research reports. Chardan Capital reiterated a “buy” rating and issued a $24.00 target price on shares of Stoke Therapeutics in a research note on Wednesday. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a research report on Tuesday, December 10th. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Stoke Therapeutics in a report on Tuesday. One research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $23.00.

Stoke Therapeutics Trading Down 2.2 %

Shares of NASDAQ STOK opened at $8.15 on Thursday. The stock has a market capitalization of $431.68 million, a PE ratio of -3.88 and a beta of 0.99. Stoke Therapeutics has a 12-month low of $5.93 and a 12-month high of $17.58. The stock’s fifty day simple moving average is $9.47 and its two-hundred day simple moving average is $11.45.

Stoke Therapeutics (NASDAQ:STOK) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.38. The firm had revenue of $22.61 million for the quarter, compared to the consensus estimate of $4.20 million. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%.

Insider Activity

In other Stoke Therapeutics news, insider Barry Ticho sold 3,884 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the completion of the transaction, the insider now owns 63,962 shares of the company’s stock, valued at approximately $554,550.54. The trade was a 5.72 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total transaction of $90,011.94. Following the sale, the director now directly owns 148,253 shares in the company, valued at approximately $1,285,353.51. The trade was a 6.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 16,532 shares of company stock valued at $143,332 in the last ninety days. Insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

A number of hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp boosted its holdings in Stoke Therapeutics by 1.4% in the 4th quarter. Bank of New York Mellon Corp now owns 93,195 shares of the company’s stock worth $1,028,000 after buying an additional 1,330 shares during the last quarter. Graham Capital Management L.P. lifted its position in shares of Stoke Therapeutics by 8.5% in the fourth quarter. Graham Capital Management L.P. now owns 18,634 shares of the company’s stock valued at $206,000 after acquiring an additional 1,453 shares in the last quarter. Gilder Gagnon Howe & Co. LLC boosted its stake in shares of Stoke Therapeutics by 2.0% in the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 92,546 shares of the company’s stock worth $1,021,000 after acquiring an additional 1,791 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Stoke Therapeutics by 6.3% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 37,455 shares of the company’s stock valued at $414,000 after purchasing an additional 2,215 shares during the last quarter. Finally, Rhumbline Advisers lifted its holdings in Stoke Therapeutics by 6.0% in the 4th quarter. Rhumbline Advisers now owns 49,374 shares of the company’s stock valued at $545,000 after purchasing an additional 2,787 shares in the last quarter.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.